Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report

Immuno-checkpoint inhibitor response and immune-related adverse events remain controversial issues. Managing pericardial effusion during programmed cell death 1 inhibitor treatment is challenging. Here, we report a case of successfully managed cardiac tamponade caused by nivolumab-induced pseudoprog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Immunotherapy 2019-04, Vol.11 (6), p.467-472
Hauptverfasser:	Asai, Maiko, Kato, Yasuhiro, Kawai, Shoko, Watanabe, Kageaki, Yomota, Makiko, Okuma, Yusuke, Hosomi, Yukio, Hishima, Tsunekazu, Okamura, Tatsuru
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adenocarcinoma of Lung - drug therapy Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Apoptosis Bleomycin Bleomycin - therapeutic use Cancer therapies cardiac tamponade Cardiac Tamponade - diagnosis Cardiac Tamponade - drug therapy Cardiac Tamponade - etiology Case reports Catheters Cell death Cellular biology Chemotherapy Computed tomography Cytotoxicity Drug-Related Side Effects and Adverse Reactions - drug therapy Dyspnea Effusion Heart Humans Hypodermic needles Immunotherapy Immunotherapy - adverse effects intrapericardial bleomycin Ligands Lung cancer Lung Neoplasms - drug therapy Lymphatic system Male Melanoma Middle Aged Monoclonal antibodies Neoplasm Recurrence, Local nivolumab Nivolumab - adverse effects Nivolumab - therapeutic use Patients PD-1 protein pericardial effusion Pericardiocentesis Pericardium programmed cell death 1 inhibitor pseudoprogression Tamponade Targeted cancer therapy Tomography, X-Ray Computed Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!